ELAN Corp. Sieg gegen Alzheimer? - 500 Beiträge pro Seite

[Börsenaga]

aus dem Biotech-Forum bei http://www.UpToTRADE.de

Betreff: ELAN ( ELN / 871331) Sieg gegen Alzheimer? mvT
Geschrieben von: fortune am Montag, 10 Juli 2000, um 3:40 p.m.

Gestern in den Tagesthemen kam ein Bericht über Alzheimer und die Forschungsergebnisse dieser Firma bezüglich der Krankheit. Hierüber steht auch in der neuesten Ausgabe der amerikanischen Zeitschrift "Nature" vom 8. Juli 00 (=letzter Samstag und damit nach Börsenschluß am Freitage...) ein Bericht.
Die Presseveröffentlichung der Firma lautet dazu wie folgt (Quelle: http://www.elan.ie/alzheimer/pressrelease.asp):
EXPERIMENTAL THERAPY MAY BE USEFUL IN TREATING AND
PREVENTING ALZHEIMER`S DISEASE

Elan Scientists Report in Nature Animal Data on Preventing Amyloid Plaques
and Brain Pathology by Immunization

AN­1792, May be Key to a Therapeutic Vaccine against Alzheimer`s Disease

Dublin, Ireland, July 8, 1999 -- A form of the very peptide that triggers the deposition
of amyloid plaque that overwhelms the brains of people with Alzheimer`s disease may
someday be used as a treatment for this devastating disease and possibly as a vaccine
to prevent it. Researchers at Elan Corporation, plc (NYSE: ELN) ("Elan") reported
today in the scientific journal, Nature, that immunization with a 42 amino acid form of
the beta-amyloid peptide (A42), called AN-1792, significantly reduced pre-existing
amyloid plaque and inhibited further plaque formation in the brains of Elan`s transgenic
(PDAPP) mouse model of Alzheimer`s disease. Elan also reported that in another study
prophylactic immunization with AN-1792 prevented the majority of treated mice from
developing virtually any amyloid plaque.

Amyloid plaque formation reduced or prevented in PDAPP mouse model of
Alzheimer`s disease

In the studies reported today, a group of PDAPP mice were immunized with
AN-1792, at an age (six-weeks) well before these mice develop amyloid plaque and
associated brain damage. At age 13 months, the brains of the mice were compared to
brains from three other groups of mice which had been inoculated with a saline solution
(control), another plaque-associated protein, (serum amyloid P component (SAP)), or
left untreated.

The group treated with AN-1792 had statistically significantly less amyloid plaque and
surrounding neuropathology than any of the other three groups (p value=0.001).
Virtually all of the mice treated with AN-1792 had no detectable amyloid deposits in
their brains. In contrast, the groups treated with either saline or SAP had no reduction
in the progressive deposition of plaques.

In a second study, a group of 11-month old female PDAPP mice (an age when
numerous amyloid plaques are already in the brain) were also treated with AN-1792.
Two parallel groups of PDAPP mice from the same litter acted as controls. Seven
months later (at age 18 months), the mice that received AN-1792 had significantly
(>99%; p value=0.0002) less plaque and neuropathology than untreated mice.
Moreover, compared to 12-month old untreated mice, the 18-month old treated mice
had fewer amyloid plaques, suggesting that the treatment facilitates the removal of
pre-existing amyloid plaque.

Commenting on the results, Dale Schenk, Ph.D., vice president of Neurobiology at
Elan said, "In our first study the virtual absence of plaques in the brains of the mice
treated with AN-1792 indicates that the deposition of amyloid was markedly reduced
or entirely eliminated. The results suggest that the immunization with AN-1792
prevented the deposition of beta-amyloid and/or accelerated its removal from brain
tissue. In the second study, the absence of the subsequent neuronal degenerative and
related inflammatory changes that usually occur around amyloid plaque suggests that
the AN-1792 treated mice never developed the degenerative lesions associated with
Alzheimer`s disease.

"Should AN-1792 prove as successful in future human clinical trials as it has been in
our preclinical mouse studies, we believe it will help treat a disease that devastates
millions of patients and their families," he added.

Elan`s President and Chief Operating Officer John Groom said, "These findings, while
preliminary, are very exciting. Based on the data published today, we expect later this
year to submit an Investigational New Drug Application with the U.S. Food and Drug
Administration to seek approval to begin Phase I clinical studies to assess the safety of
AN-1792 in humans."

`Amyloid Hypothesis` leads to AN-1792 as a potential new treatment for
Alzheimer`s disease

From the first observations made by Dr. Alois Alzheimer in 1906, scientists have long
observed the presence of many beta-amyloid plaques in the brain tissue of people who
died with Alzheimer`s disease. Pathologists, who observe these plaques upon autopsy,
say it looks like insoluble protein build-up has stifled surrounding brain cells. Many
Alzheimer`s disease experts hypothesize that it is the presence of these plaques that
leads to the brain damage which causes the devastation of a person`s memory and
thinking ability (cognitive functions).

"Through the course of our research and that of our collaborators we recognized that
blocking the process by which amyloid plaque develops and accumulates in the brain
might enable physicians to treat Alzheimer`s disease at its source. Since amyloid plaque
is essentially a brain invader, we wondered if it could be controlled like other invasive
substances -- by immunization," said Ivan Lieberburg, M.D., Ph.D., senior vice
president of Research at Elan.

Alzheimer`s disease ­ A growing healthcare problem

Alzheimer`s disease is a progressive, degenerative disease of the brain. It primarily
afflicts older persons and begins with symptoms such as simple confusion and
forgetfulness. Ultimately, Alzheimer`s disease leads to profound dementia. Patients may
undergo wrenching personality changes, and eventually become unable to care for
themselves or to be cared for outside of an institutional setting.

Approximately four million people in the U.S. have Alzheimer`s disease. It affects one
person in 10 over age 65, and almost half of all persons over age 85. These are the
two most rapidly growing population segments in North America, Western Europe and
Japan. According to the Alzheimer`s Association the overall cost of Alzheimer`s disease
to families and society in the U.S. is estimated at $80-100 billion annually.

"Elan`s findings are particularly important because of the significant need for therapies
that can alter the course of Alzheimer`s disease, something that does not exist today. I
am delighted that Elan`s long commitment to research on Alzheimer`s disease has lead
us to this important milestone and I congratulate the many Elan scientists involved in this
breakthrough," commented Donal Geaney, Elan`s Chairman and Chief Executive
Officer.

Elan Corporation, plc is a leading worldwide specialty pharmaceutical company
headquartered in Ireland, with its principal research, development, manufacturing, and
marketing facilities located in Ireland, the United States and Israel. Elan`s shares trade
on the New York, London and Dublin Stock Exchanges.

The statements in this press release may include forward-looking statements that
involve risks and uncertainties including, the successful completion of preclinical and
clinical studies and the difficulty of predicting regulatory approvals, as well as the other
risks and uncertainties detailed from time to time in periodic reports, including Elan`s
annual report on Form 20-F for the year ended December 31, 1998, filed with the
Securities and Exchange Commission. Actual results may differ from the
forward-looking statements.

For more information call : 1-888-638-7605 Monday to Friday between 9 AM -
5 PM EDT Or E-Mail: Alison Becker
Please note : The number is located in the United States.

http://www.siteboard.de/cgi-siteboard/board.pl?fnr=8966&read…

[Börsenaga]

soll man in diesen Wert einsteigen?

[niceguy11]

ich denke JA
habe heute mein Depot bei 53,- ein bißchen erweitert.

[Börsenaga]

Danke !

[Laurin]

Bin schon seit einiger Zeit in Elan drin, - die Alzheimer-"Impfung" ist nur das Sahnehaeubchen. Elan hat gerade von der FDA in USA die Zulassung fuer ein neues Medikament bekommen und noch drei weitere stehen (kurz) vor der Zulassung. Sehr ausfuehrliche Informationen findet ihr beim IndividualInvestor (Einstieg z.B. ueber die Yahoo-stock-quotes-Seite), die Elan in ihrem Magic-25 Depot haben. Elan wird gerade erst als specialty pharmaceutical company entdeckt und ist im Vergleich zu anderen Unternhemen der Branche noch sehr preiswert. Ausserdem tauchen immer wieder buyout-Geruechte auf (Elan wuerde gut zu Bayer passen, aber das ist nur meine persoenliche Meinung).

Gruss aus USA --- Laurin

[bartleby]

Schaut mal vorbei auf CNN.com.
Dort größerer Artikel über Elan unter "Alzheimer´ s vaccine appears safe in human testing ".

Gruß, Bartleby

[only4fun]

Princeton, New Jersey, July 12 (Bloomberg Data) -- Elan Corp Plc -spons Adr (ELN US) was reiterated short-term ``outperform`` by analyst Jeffrey J Kraws at Gruntal & Co. The long-term rating was also reiterated ``outperform.`` The short/long-term target prices are $58/$70 per share.

[Börsenaga]

werde dann mal am Montag ein paar Stücke kaufen.

[Deppi]

mmmm?